Hologic, Inc. (NASDAQ:HOLX)‘s stock had its “neutral” rating restated by equities research analysts at Bank of America Corporation in a note issued to investors on Friday. They currently have a $48.00 price objective on the medical equipment provider’s stock, up from their previous price objective of $44.00. Bank of America Corporation’s price objective would suggest a potential upside of 6.64% from the stock’s current price.

A number of other analysts have also weighed in on HOLX. Jefferies Group LLC set a $49.00 price objective on shares of Hologic and gave the company a “buy” rating in a research note on Sunday, May 28th. Stifel Nicolaus restated a “buy” rating on shares of Hologic in a research note on Friday, July 14th. Barclays PLC restated an “overweight” rating and set a $53.00 price objective (up from $50.00) on shares of Hologic in a research note on Monday, July 17th. Piper Jaffray Companies restated a “buy” rating and set a $51.00 price objective on shares of Hologic in a research note on Friday, July 14th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $52.00 price target on shares of Hologic in a report on Thursday, March 30th. One analyst has rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the company’s stock. Hologic currently has a consensus rating of “Buy” and an average target price of $47.79.

Hologic (NASDAQ:HOLX) opened at 45.01 on Friday. Hologic has a 12-month low of $35.15 and a 12-month high of $46.80. The stock has a market capitalization of $12.60 billion, a PE ratio of 16.14 and a beta of 0.91. The company’s 50-day moving average is $45.08 and its 200 day moving average is $42.70.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.04. The business had revenue of $715.40 million during the quarter, compared to analyst estimates of $685.24 million. Hologic had a net margin of 27.31% and a return on equity of 25.26%. Hologic’s revenue was up 3.2% compared to the same quarter last year. During the same period last year, the business earned $0.47 EPS. On average, equities research analysts expect that Hologic will post $2.01 earnings per share for the current fiscal year.

WARNING: “Bank of America Corporation Reiterates Neutral Rating for Hologic, Inc. (NASDAQ:HOLX)” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/07/23/bank-of-america-corporation-reiterates-neutral-rating-for-hologic-inc-nasdaqholx.html.

In related news, Director Sally Crawford sold 16,969 shares of the firm’s stock in a transaction that occurred on Monday, April 24th. The shares were sold at an average price of $44.00, for a total value of $746,636.00. Following the transaction, the director now owns 157,305 shares of the company’s stock, valued at $6,921,420. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Karleen Marie Oberton sold 4,704 shares of the firm’s stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $45.19, for a total transaction of $212,573.76. The disclosure for this sale can be found here. In the last three months, insiders sold 101,108 shares of company stock worth $4,469,012. 0.79% of the stock is currently owned by insiders.

Several institutional investors have recently bought and sold shares of HOLX. Cleararc Capital Inc. increased its position in Hologic by 1.1% in the first quarter. Cleararc Capital Inc. now owns 6,843 shares of the medical equipment provider’s stock worth $291,000 after buying an additional 77 shares during the last quarter. Compton Capital Management Inc. RI increased its position in Hologic by 0.6% in the first quarter. Compton Capital Management Inc. RI now owns 16,810 shares of the medical equipment provider’s stock worth $715,000 after buying an additional 100 shares during the last quarter. Advantus Capital Management Inc increased its position in Hologic by 0.4% in the first quarter. Advantus Capital Management Inc now owns 27,936 shares of the medical equipment provider’s stock worth $1,189,000 after buying an additional 116 shares during the last quarter. Shell Asset Management Co. increased its position in Hologic by 0.7% in the first quarter. Shell Asset Management Co. now owns 24,647 shares of the medical equipment provider’s stock worth $1,049,000 after buying an additional 182 shares during the last quarter. Finally, Curbstone Financial Management Corp increased its position in Hologic by 2.4% in the second quarter. Curbstone Financial Management Corp now owns 8,678 shares of the medical equipment provider’s stock worth $394,000 after buying an additional 200 shares during the last quarter. 94.04% of the stock is currently owned by institutional investors.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.